

# Regulatory Story

[Go to market news section](#)



**Intl. Biotechnology Trust PLC - IBT**  
Portfolio Update  
Released 15:15 21-Mar-2018

RNS Number : 4930I  
Intl. Biotechnology Trust PLC  
21 March 2018

## **INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)**

### **Portfolio Update as at 28 February 2018**

Net Assets	£227m
Net Assets per share	605p
Share price	586p
Total value of unquoted investments	£22m
Total number of portfolio companies	95
Dividend	4% of NAV per annum

### **Top Ten Quoted Investments**

<b>Company Name</b>	<b>% NAV</b>
Array	4.7
Biogen	4.2
Celgene	4.2
Neurocrine	4.2
Regeneron	3.7
Genmab	3.7
Sage	3.6
Vertex	3.6
Gilead	3.3
Exelixis	3.2
	-----
	-
Total	38.4

### **Geographical Allocation**

**% NAV**

US & Canada	89
Europe & UK	11
	-----
	-
Total	100

<b>Quoted/Unquoted Allocation</b>	<b>% NAV</b>
Quoted	91
Unquoted	9
	-----
	-
Total	100

<b>NAV % Market Cap</b>	<b>% NAV</b>
Large Cap >USD10BN	36
Mid Cap =USD1-10BN	37
Small Cap <USD1BN	27
	-----
	-
Total	100

<b>NAV % by Therapeutic Areas</b>	<b>% NAV</b>
Oncology	38
Rare diseases	15
CNS	14
Inflammation	6
Ophthalmology	6
Metabolic	5
Infectious Diseases	4
Medtech	4
Other	8
	-----
	-
Total	100

**BNP Paribas Secretarial Services Limited**  
Company Secretary

21 MARCH 2018

This information is provided by RNS  
The company news service from the London Stock Exchange